10
Feb

Academics call time on $100,000 cancer drugs

A group of academic researchers has demanded an end to cancer medicines costing more than $100,000 a year and proposed a new model of low-cost drug development that would capitalize on recent advances in science.

The spiraling cost of cancer medicines is a growing concern for doctors and their patients, many of whom struggle to pay for new medicines that often cost $10,000 a month.

Sky-high prices have made oncology hugely profitable, with IMS Health forecasting global cancer drug sales of at least $150 billion by 2020. Scientists, however, believe today’s prices are simply not sustainable as more and more people need treatment.

Read Full Article Here >>